Risk factors
Vericel (VCEL) risk factors
Item 1A of every Vericel Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors62 risks6 new9 dropped15 reworded
Profitability is improving, but future losses remain possible as Vericel funds MACI Arthro, MACI Ankle, manufacturing, and international expansion.
Filed Feb 26, 2026 - FY2024 10-K risk factors65 risks
Vericel faces concentration risk in its marketed products MACI, Epicel, and NexoBrid. Heavy reliance on third-party manufacturers like Matricel and MediWound threatens commercialization. Strict regulatory oversight and healthcare reimbursement policies directly impact operational profitability.
Filed Feb 27, 2025